MX366317B - Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. - Google Patents

Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.

Info

Publication number
MX366317B
MX366317B MX2015009058A MX2015009058A MX366317B MX 366317 B MX366317 B MX 366317B MX 2015009058 A MX2015009058 A MX 2015009058A MX 2015009058 A MX2015009058 A MX 2015009058A MX 366317 B MX366317 B MX 366317B
Authority
MX
Mexico
Prior art keywords
methods
chronic inflammation
compositions
inflammatory diseases
treat chronic
Prior art date
Application number
MX2015009058A
Other languages
English (en)
Spanish (es)
Other versions
MX2015009058A (es
Inventor
Brew John
Mark Bannister Robin
Jane Dilly Suzanne
Alan Stoloff Gregory
Caparrós-Wanderley Wilson
Pleguezuelos Mateo Olga
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Publication of MX2015009058A publication Critical patent/MX2015009058A/es
Publication of MX366317B publication Critical patent/MX366317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2015009058A 2013-02-04 2014-01-14 Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. MX366317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752309P 2013-02-04 2013-02-04
PCT/EP2014/050627 WO2014117999A1 (en) 2013-02-04 2014-01-14 Compositions and methods for treating chronic inflammation and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2015009058A MX2015009058A (es) 2016-01-08
MX366317B true MX366317B (es) 2019-07-03

Family

ID=50150686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009058A MX366317B (es) 2013-02-04 2014-01-14 Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.

Country Status (14)

Country Link
EP (1) EP2950821A1 (enExample)
JP (1) JP6474352B2 (enExample)
KR (1) KR20150129664A (enExample)
CN (1) CN105120900A (enExample)
AU (1) AU2014211715B2 (enExample)
BR (1) BR112015015870B1 (enExample)
CA (1) CA2898017A1 (enExample)
HK (1) HK1218621A1 (enExample)
IL (1) IL239920A0 (enExample)
MX (1) MX366317B (enExample)
RU (1) RU2680801C2 (enExample)
SG (1) SG11201505243PA (enExample)
WO (1) WO2014117999A1 (enExample)
ZA (1) ZA201505006B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
EP3313519B1 (en) * 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
CN108283637A (zh) * 2018-04-04 2018-07-17 无锡市儿童医院 辛伐他汀的应用
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use
CN114051410A (zh) 2019-04-30 2022-02-15 白雁生物技术公司 包含分离的线粒体为有效成分的预防或治疗肌炎的药物组合物
CN114555103B (zh) * 2019-06-03 2026-06-05 伊美诺路克斯国际公司 用于治疗疾病的天花疫苗和干细胞
MX2022005168A (es) * 2019-11-06 2022-06-08 Smartech Topical Inc Formulaciones topicas de inhibidores de la ciclooxigenasa y su uso.
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2752764C1 (ru) * 2020-12-14 2021-08-03 Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") Фармацевтическая композиция, обладающая противовоспалительным действием
AU2022248850A1 (en) 2021-03-27 2023-11-09 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics
RU2760220C1 (ru) * 2021-06-02 2021-11-22 Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Способ определения клинически значимой усталости у больного ревматоидным артритом на фоне 5-летней терапии базисными противовоспалительными препаратами или базисными противовоспалительными препаратами в комплексе с генно-инженерными биологическими препаратами и/или психофармакотерапией и сопутствующего расстройства тревожно-депрессивного спектра
WO2025122472A1 (en) * 2023-12-04 2025-06-12 Primus Pharmaceuticals, Inc. Emollient compositions comprising linoleic acid and conjugated linoleic acid and methods of use
WO2026132760A1 (en) * 2024-12-19 2026-06-25 IBUMIX Ltd Lipophilic drug suspensions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2369594A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
JP2007500691A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗炎症剤の分散性製剤
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
AU2006240551A1 (en) * 2005-04-28 2006-11-02 Dsm Ip Assets B.V. Pharmaceutical dosage forms comprising a lipid phase
US20070249725A1 (en) * 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
ES2423793T3 (es) 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
WO2012104655A2 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases

Also Published As

Publication number Publication date
JP2016506941A (ja) 2016-03-07
AU2014211715B2 (en) 2016-08-25
MX2015009058A (es) 2016-01-08
CN105120900A (zh) 2015-12-02
ZA201505006B (en) 2016-03-30
HK1218621A1 (zh) 2017-03-03
EP2950821A1 (en) 2015-12-09
BR112015015870A8 (pt) 2018-01-16
BR112015015870A2 (pt) 2017-07-11
RU2015137659A (ru) 2017-03-10
WO2014117999A1 (en) 2014-08-07
AU2014211715A1 (en) 2015-07-23
CA2898017A1 (en) 2014-08-07
BR112015015870B1 (pt) 2022-09-27
KR20150129664A (ko) 2015-11-20
IL239920A0 (en) 2015-08-31
SG11201505243PA (en) 2015-08-28
JP6474352B2 (ja) 2019-02-27
RU2680801C2 (ru) 2019-02-27

Similar Documents

Publication Publication Date Title
UY40476A (es) Moléculas de anticuerpo que se unen a tim-3 y usos de las mismas
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
UY40389A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
SI4000608T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
HUE046671T2 (hu) Glutárimid származékokat tartalmazó gyógyászati készítmény, valamint ennek alkalmazása eozinofil betegségek kezelésében
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
AR130700A2 (es) Composiciones de grapiprant y métodos para su utilización
DOP2015000290A (es) Benzoxazoles sustituidos
IN2013MU03855A (enExample)
PT3052476T (pt) Inibidores de nicotinimida substituídos de btk e sua preparação e uso no tratamento do cancro, inflamações e doenças autoimunes

Legal Events

Date Code Title Description
FG Grant or registration